BromSite demonstrated statistically significant superiority compared with vehicle in a phase 3 clinical trial that evaluated the reduction of pain and inflammation after cataract surgery, according to a press release from InSite Vision.
InSite intends to begin a second phase 3 trial of BromSite (ISV-303), which combines 0.075% bromfenac with the proprietary DuraSite drug delivery system, in order to speed potential regulatory approvals in the United States and Europe, according to the release.